Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Hilmi

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Bulletin Du Cancer|September 11, 2024
[NALIRIFOX in first-line therapy for metastatic pancreatic adenocarcinoma]Siriane Anglaret, Marc Hilmi
Bulletin Du Cancer|September 18, 2020
[New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation]Marc Hilmi, Cindy Neuzillet
World Journal of Gastroenterology|June 2, 2018
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?Marc Hilmi, Laurent Bartholin, Cindy Neuzillet
Cancers|October 17, 2020
Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune EvasionMarc Hilmi, Rémy Nicolle, Corinne Bousquet, et al.
Current Issues in Molecular Biology|June 9, 2022
Whole-Transcriptome Profiling on Small FFPE Samples: Which Sequencing Kit Should Be Used?Marc Hilmi, Lucile Armenoult, Mira Ayadi, et al.
Cancers|January 2, 2020
Immune Therapy for Liver CancersMarc Hilmi, Angélique Vienot, Benoît Rousseau, et al.
Gastroenterology|January 6, 2025
Fibroblast Activation Protein Expression Is Scarce in Epithelial CellsMarc Hilmi, Caroline Sophie Verbeke, Rémy Nicolle, et al.
Critical Reviews in Oncology/Hematology|April 30, 2021
Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatmentsPaul Gougis, Marc Hilmi, Arthur Geraud, et al.
Cancers|June 2, 2021
Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?Alice Boilève, Marc Hilmi, Matthieu Delaye, et al.
Cancers|April 3, 2021
Immunotherapy in Advanced Biliary Tract CancersAlice Boilève, Marc Hilmi, Cristina Smolenschi, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Bulletin Du Cancer|September 11, 2024
[NALIRIFOX in first-line therapy for metastatic pancreatic adenocarcinoma]Siriane Anglaret, Marc Hilmi
Bulletin Du Cancer|September 18, 2020
[New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation]Marc Hilmi, Cindy Neuzillet
World Journal of Gastroenterology|June 2, 2018
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?Marc Hilmi, Laurent Bartholin, Cindy Neuzillet
Cancers|October 17, 2020
Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune EvasionMarc Hilmi, Rémy Nicolle, Corinne Bousquet, et al.
Current Issues in Molecular Biology|June 9, 2022
Whole-Transcriptome Profiling on Small FFPE Samples: Which Sequencing Kit Should Be Used?Marc Hilmi, Lucile Armenoult, Mira Ayadi, et al.
Cancers|January 2, 2020
Immune Therapy for Liver CancersMarc Hilmi, Angélique Vienot, Benoît Rousseau, et al.
Gastroenterology|January 6, 2025
Fibroblast Activation Protein Expression Is Scarce in Epithelial CellsMarc Hilmi, Caroline Sophie Verbeke, Rémy Nicolle, et al.
Critical Reviews in Oncology/Hematology|April 30, 2021
Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatmentsPaul Gougis, Marc Hilmi, Arthur Geraud, et al.
Cancers|June 2, 2021
Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?Alice Boilève, Marc Hilmi, Matthieu Delaye, et al.
Cancers|April 3, 2021
Immunotherapy in Advanced Biliary Tract CancersAlice Boilève, Marc Hilmi, Cristina Smolenschi, et al.
Pageof 5